Future Planet Capital was among the investors that added an undisclosed sum to the $10m in series B funding Congenica raised in February.

Congenica, a UK-based clinical genomics software developer, has closed a series B round of undisclosed size after securing additional funding from investors including spinout-focused investment firm Future Planet Capital.

The second tranche also featured genomics technology provider BGI Genomics and healthcare services provider Healthlink.

Congenica previously achieved a $10m first close in February led by Cambridge University’s patient capital fund Cambridge Innovation Capital, with participation from spinout-focused investment firm Parkwalk Advisors and Amadeus Capital Partners.

Congenica has built a software platform called Sapientia that analyses data on genome-scale DNA in order to compile a detailed diagnostic report for each patient that can be used to help inform clinical decisions for rare genetic diseases.

The company is exploiting research conducted the Sanger Institute based at the Wellcome Genome Campus.

Healthlink’s clinical diagnostics lab, UniteGen, and BGI have both signed contracts to use Sapientia in their respective operations. Healthlink participated in the round through its Healthlink Capital subsidiary.

Congenica had previously raised £3.2m in funding, securing £1m in seed capital from CIC in late 2014 before adding £2.2m in series A funding from CIC and Amadeus the following year.

Tom Weaver, chief executive of Congenica, said: “This additional investment enhances our ability and commitment to deploy our software platform to international markets. Particularly China, where we have established a scalable partnering model to transform the clinical genetic testing market.

“Genomic technology will be central to the next generation healthcare system that is evolving rapidly in China and we are delighted to be working with strategic partners, both at the financial and commercial level, who are at the forefront of that change and committed to the benefits it will bring to patients.”

– A version of this article first appeared on our sister site Global Corporate Venturing.